Drug Trial Radar · NCT07768189
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
260
Planned (sponsor's estimate)
Start
Sep 29, 2026
Primary completion
Dec 2027
Study completion Mar 2029
Sponsor
- Lead sponsor
- Corbus Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- Collaborators
- CSPC Megalith Biopharmaceutical Co.,Ltd.
- First posted
- Aug 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to understand whether CRB-701, a targeted form of chemotherapy called an anti-body drug conjugate, will work as a treatment for oropharyngeal (throat, tonsil) cancer. In patients who have already received platinum based chemotherapy or immunotherapy (using a check-point inhibitor) It will also learn about the safety of the drug and measure quality of life. The main questions it asks are: * What proportion of participants respond to CRB-701 measured using scans (CT or MRI) * What medical problems do participants experience when taking CRB-701. Researchers will compare CRB-701 with standard of care medicines (drugs that are normally used this disease). Participants will: * Attend clinic every three weeks to receive infusions of CRB-701 or standard of care medicines until the cancer cannot be measured or is not controlled by the treatment they are receiving. * Have a CT or MRI every 6 weeks to measure the effect on their cancer * Complete questionnaires to assess their health status.
Conditions
- Oropharyngeal Carcinoma (OPC)
Interventions
CRB-701Drug
CRB-701 3.6mg/Kg administered intravenously every 21 days (Q3W)
capcitabineDrug
1250 mg/m2 twice daily on days 1-14 of each 21-day cycle
Cetuximab (EGFR inhibitor)Drug
400mg/m2 loading dose followed by 250mg/m2 weekly as an IV infusion or 500mg/m2 every 2 weeks.
DocetaxelDrug
75 mg/m2 as an IV infusion on day 1 of each 21-day cycle or 30 mg/m2 weekly to escalate to 40 mg/m2, if tolerated.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (%)Time frame: Up to 24 months
- Overall Survival (months)Time frame: Approximately 3 years from randomization
Locations
111 sites in 14 countries. Site status is shown where the registry gives one.
Clearview Cancer Institute
Huntsville, Alabama · Not yet recruiting
The University of Arizona Cancer Center
Tucson, Arizona · Not yet recruiting
City of Hope Comprehensive Cancer Center
Duarte, California · Not yet recruiting
University of California Los Angeles Westwood Cancer Center
Los Angeles, California · Not yet recruiting
Stanford Medicine - Cancer Center
Palo Alto, California · Not yet recruiting
Moores Cancer Center
San Diego, California · Not yet recruiting
UCSF Head and Neck Surgery Cancer Program
San Francisco, California · Not yet recruiting
UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado
Colorado Springs, Colorado · Not yet recruiting
Yale School of Medicine
Newhaven, Connecticut · Not yet recruiting
Medical Oncology Hematology Consultants
Newark, Delaware · Not yet recruiting
Florida Cancer Specialists and Research Institute
Orlando, Florida · Recruiting
Moffitt Cancer Center Magnolia Campus
Tampa, Florida · Not yet recruiting
University of Chicago
Chicago, Illinois · Not yet recruiting
Iowa Health Care Holden Comprehensive Cancer Center
Iowa City, Iowa · Not yet recruiting
University of Louisville Health
Louisville, Kentucky · Not yet recruiting
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
Baltimore, Maryland · Not yet recruiting
Greater Baltimore Medical Center
Baltimore, Maryland · Not yet recruiting
Dana Faber Cancer Institute
Boston, Massachusetts · Not yet recruiting
Barbara Ann Karmanos Cancer Institute - Wayne State University
Detroit, Michigan · Not yet recruiting
Mayo Clinic in Rochester
Rochester, Minnesota · Not yet recruiting
Washington University in St. Louis
St Louis, Missouri · Not yet recruiting
Nebraska Cancer Specialists - Methodist Estabrook Cancer Center
Omaha, Nebraska · Recruiting
NYU Langone Health Perlmutter Cancer Center
New York, New York · Not yet recruiting
Memorial Sloan Kettering
New York, New York · Not yet recruiting
Gabrail Cancer Center and Research Center
Canton, Ohio · Recruiting
Cleveland Clinic Main Campus
Cleveland, Ohio · Not yet recruiting
The Ohio State University Comprehensive Cancer Center The Arthur G.James
Columbus, Ohio · Not yet recruiting
Penn-Medicine - Abramson Cancer Center University of Pennsylvania
Philadelphia, Pennsylvania · Not yet recruiting
Fox Chase Cancer Center
Philadelphia, Pennsylvania · Not yet recruiting
MUSC Hollings Cancer Center
Charleston, South Carolina · Not yet recruiting
Prisma Health Cancer Institute Multidisciplinary Center
Greenville, South Carolina · Not yet recruiting
Tennessee Cancer Specialists
Knoxville, Tennessee · Not yet recruiting
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee · Not yet recruiting
Texas Oncology
Austin, Texas · Not yet recruiting
Texas Oncology
Dallas, Texas · Not yet recruiting
UVA Health - Emily Couric Clinical Cancer Center
Charlottesville, Virginia · Not yet recruiting
Fred Hutchinson Cancer Center Clinical - Seattle Cancer Care Alliance
Seattle, Washington · Not yet recruiting
Northwest Cancer Center
Vancouver, Washington · Not yet recruiting
Ordensklinikum Linz Barmherzige Schwestern
Linz, Austria · Not yet recruiting
University Hospital Vienna
Vienna, Austria · Not yet recruiting
Showing 40 of 111 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.